查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1828014

神经保护市场（依产品类型、作用机制、最终用户、适应症和通路划分）－2025-2032 年全球预测

Neuroprotection Market by Product Type, Mechanism Of Action, End User, Indication, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年神经保护市场规模将成长至 5,738 亿美元，复合年增长率为 7.92%。

主要市场统计数据
基准年2024年 3117.9亿美元
预计2025年 3363.1亿美元
预测年份：2032年 5738亿美元
复合年增长率（%） 7.92%

全面介绍当前的神经保护科学、​​治疗方法和战略重点，为临床和商业性决策提供信息

本执行摘要综合了当今定义神经保护的科学进展、监管动态、商业性驱动因素和营运考虑。近几十年来，人们对神经元存活途径、发炎连锁、兴奋性毒性损伤和再生策略的理解日益加深；这些生物学见解正与新型治疗方法相结合，重塑临床治疗方案。转化研究如今涵盖了从传统的小分子神经保护剂到复杂的生物製药、基因调节疗法和基于细胞的干预措施，从而形成了一个多方面的格局，其中治疗方法差异取决于机制的精确性、递送技术和患者分层。

随着相关人员对这些发展趋势的掌握，重点正从单一目标转向整合抗发炎控制、抗氧化防御、离子通道活性调节和神经营养讯号传递支援的整合策略。同时，监管机构对安全性、生物标记检验和长期疗效的期望也要求制定全面的证据生成计划。因此，决策者必须平衡科学机会与实际考虑因素，例如製造复杂性、通路和临床治疗途径，以确保创新成果易于获取并转化为持续的临床效益。

科学进步、交付创新和不断变化的相关人员期望如何从根本上改变临床和商业性神经保护格局

科学、技术和政策力量的融合正在改变神经保护领域。分子生物学和精准医疗框架的进步使得能够针对特定病理学机制的标靶治疗成为可能，而给药系统和生物标记主导的试验设计的改进则提高了证明有意义临床益处的能力。与科学进步同步，用于远端监控和自适应临床试验方法的数位健康工具的应用正在加速证据生成和患者参与，重塑治疗方法从实验室走向临床的方式。

此外，新一代治疗方法的成本和复杂性促使生物技术、学术中心和合约研究组织之间建立新的伙伴关係结构。这一趋势正在推动向合作模式的转变，该模式旨在分散风险、集中专业製造能力，并在开发早期整合监管策略。同时，付款人和医疗保健系统对强有力的真实世界证据和经济价值证明的要求日益提高，这促使研发人员将长期疗效、护理路径整合和上市后绩效评估作为其专案规划的核心组成部分。

评估近期关税政策如何影响神经保护疗法开发中的供应链弹性、筹资策略和製造地点决策

贸易措施和关税相关政策行动的增多，为支持神经保护疗法的全球供应链带来了新的复杂性。进口成本的上升可能会扰乱活性药物成分、生物製药材料、基因和细胞疗法专用试剂以及关键包装零件的采购，从而给筹资策略策略和库存管理带来压力。因此，製造商和供应商正在重新评估供应商冗余、库存缓衝和物流路线，以降低生产中断的风险，同时确保符合低温运输和品质要求。

此外，关税带来的成本压力可能会影响製造和灌装作业选址的策略决策。加快某些製造流程的在奖励或协商长期供应商协议以稳定投入供应，有实际的激励措施。对于早期开发商而言，这些动态可能会改变与合作伙伴的谈判，因为合约开发商和製造外包可能会根据不断变化的跨境经济状况调整产能分配。这些因素加在一起，要求相关人员将贸易政策情境纳入专案级风险评估和采购方案，以维持开发进度和供应的连续性。

详细的细分情报揭示了产品类型、作用机制、最终用户、适应症和分销管道如何相互作用以形成策略和执行

細項分析揭示了不同产品类型和治疗方法中存在着微妙的机会和限制。按产品类型划分，该细分市场涵盖生物製药、药品、基因疗法、营养保健品和干细胞疗法。在生物製药领域，单株抗体生物製药和神经营养因子生物製药之间的差异决定了其製造的复杂性和监管途径。在营养保健品领域，此细分市场包括草药萃取物营养保健品、矿物质营养保健品和维生素营养保健品，每种营养保健品都有不同的实证基础和分销动态。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 针对多发性硬化症患者神经发炎路径的基因编辑疗法的出现
  • 采用穿戴式神经刺激装置对慢性偏头痛症状进行个人化管理
  • 人工智慧驱动的生物标记整合，用于阿兹海默症的早期诊断和进展监测
  • 开发渗透性血脑障壁的小分子用于急性缺血性脑中风干预
  • 增加对利用神经干细胞修復脊髓损伤的细胞治疗方法的投资
  • 利用脂质奈米颗粒平台对帕金森氏症进行基于RNA的神经保护治疗

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章神经保护市场（依产品类型）

  • 生物製药
    • 单株抗体生技药品
    • 神经营养因子生物製药
  • 药物
    • 胜肽类药物
    • 小分子药物
  • 基因治疗
  • 营养补充品
    • 草本萃取物膳食补充剂
    • 矿物质营养补充品
    • 维生素营养补充品
  • 干细胞疗法

9. 神经保护市场（依作用机制）

  • 抗发炎药
    • 细胞激素抑制剂、抗发炎药
    • NSAID抗发炎药
    • 类固醇抗发炎药
  • 抗氧化剂
    • 黄酮类抗氧化剂
    • 维生素C抗氧化剂
    • 维生素E抗氧化剂
  • 钙离子通道阻断剂
    • 离胺酸钙离子通道阻断剂
    • 尼莫地平钙离子通道阻断剂
  • 麸胺酸抑制剂
  • 神经营养因子
  • NMDA拮抗剂
    • 氯胺酮 NMDA 拮抗剂
    • MemantineNMDA拮抗剂

第 10 章神经保护市场（按最终用户）

  • 诊所
  • 家庭医疗保健
  • 医院
  • 研究机构

第 11 章神经保护市场（按适应症）

  • 阿兹海默症
    • 早期阿兹海默症
    • 中度阿兹海默症
    • 严重的阿兹海默症
  • 多发性硬化症
    • 復发型多发性硬化症
    • 进行性性多发性硬化症
  • 帕金森氏症
    • 姿势不稳帕金森氏症
    • 震颤为主的帕金森氏症
  • 脊髓损伤
  • 中风
    • 出血性中风
    • 缺血性中风
  • 创伤性脑损伤

第 12 章神经保护市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第十三章神经保护市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章神经保护市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按国家/地区分類的神经保护市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Eli Lilly and Company
    • Roche Holding AG
    • Novartis AG
    • AstraZeneca PLC
    • Biogen Inc.
    • Pfizer Inc.
    • AbbVie Inc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
Product Code: MRR-430D42AA0F33

The Neuroprotection Market is projected to grow by USD 573.80 billion at a CAGR of 7.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 311.79 billion
Estimated Year [2025] USD 336.31 billion
Forecast Year [2032] USD 573.80 billion
CAGR (%) 7.92%

A comprehensive orientation to the current neuroprotection science, therapeutic modalities, and strategic priorities informing clinical and commercial decision-making

This executive summary synthesizes the scientific advances, regulatory dynamics, commercial drivers, and operational considerations defining neuroprotection today. Recent decades have produced a layered understanding of neuronal survival pathways, inflammatory cascades, excitotoxic injury, and regenerative strategies, and these biological insights are converging with new therapeutic modalities to reshape clinical approaches. Translational research now spans traditional small molecule neuroprotectants through complex biologics, gene modulation therapies, and cell-based interventions, creating a multifaceted landscape where therapeutic differentiation depends on mechanism precision, delivery technologies, and patient stratification.

As stakeholders navigate these developments, the emphasis shifts from single-target approaches to integrated strategies that combine anti-inflammatory control, antioxidant defenses, modulation of ion channel activity, and support for neurotrophic signaling. Simultaneously, regulatory expectations for safety, biomarker validation, and long-term outcomes demand integrated evidence generation plans. Therefore, decision-makers must balance scientific opportunity with pragmatic considerations such as manufacturing complexity, distribution channels, and clinical care pathways to ensure that innovation translates to accessible and durable clinical benefit.

How converging scientific advances, delivery innovations, and evolving stakeholder expectations are fundamentally reshaping the clinical and commercial neuroprotection landscape

The neuroprotection landscape is undergoing transformative shifts driven by converging scientific, technological, and policy forces. Advances in molecular biology and precision medicine frameworks are enabling targeted approaches that address specific pathophysiological mechanisms, while improvements in delivery systems and biomarker-driven trial design are enhancing the ability to demonstrate meaningful clinical effect. Alongside scientific evolution, the adoption of digital health tools for remote monitoring and adaptive clinical trial methodologies has accelerated evidence generation and patient engagement, reshaping how therapies move from bench to bedside.

Furthermore, the cost and complexity of next-generation modalities have catalyzed new partnership structures between biotech, academic centers, and contract development organizations. This trend is prompting a reorientation towards collaborative models that distribute risk, concentrate specialized manufacturing capacity, and integrate regulatory strategy earlier in development. In parallel, payers and health systems increasingly demand robust real-world evidence and economic value demonstration, pushing developers to consider long-term outcomes, care pathway integration, and post-market performance measurements as core components of program planning.

Assessment of how recent tariff policies are influencing supply chain resilience, procurement strategy, and manufacturing location decisions across neuroprotective therapeutic development

Elevated trade measures and tariff-related policy actions have introduced new layers of complexity to global supply chains supporting neuroprotective therapeutics. The sourcing of active pharmaceutical ingredients, biologic raw materials, specialized reagents for gene and cell therapies, and critical packaging components can be disrupted by increased import costs, creating pressure on procurement strategies and inventory management. As a result, manufacturers and suppliers are reevaluating supplier redundancy, inventory buffers, and logistics routing to mitigate the risk of production interruptions while preserving compliance with cold-chain and quality requirements.

In addition, tariff-driven cost pressures can influence strategic decisions about where to situate manufacturing and fill-finish operations. There is an observable incentive to accelerate localization of certain production steps or to negotiate long-term supplier agreements to stabilize input availability. For early-stage developers, these dynamics may alter partnering conversations, because contract development and manufacturing organizations may shift capacity allocation in response to changes in cross-border economics. Collectively, these factors demand that stakeholders integrate trade policy scenarios into program-level risk assessments and procurement playbooks to preserve development timelines and maintain supply continuity.

In-depth segmentation intelligence revealing how product types, mechanisms of action, end users, indications, and distribution channels interact to shape strategy and execution

Segmentation analysis reveals nuanced opportunities and constraints across product types and therapeutic approaches. Based on Product Type, the landscape spans Biologics, Drugs, Gene Therapy, Nutraceuticals, and Stem Cell Therapy. Within Biologics the differentiation between Monoclonal Antibody Biologics and Neurotrophic Factor Biologics determines manufacturing complexity and regulatory pathways, while Drugs encompass Peptide Drugs and Small Molecule Drugs with distinct delivery considerations and formulation challenges. Nutraceuticals extend into Herbal Extract Nutraceuticals, Mineral Nutraceuticals, and Vitamin Nutraceuticals, each carrying different evidentiary expectations and distribution dynamics, and Stem Cell Therapy presents unique infrastructure and regulatory oversight requirements.

Based on Mechanism Of Action, the field incorporates Anti Inflammatory Agents, Antioxidants, Calcium Channel Blockers, Glutamate Inhibitors, Neurotrophic Factors, and NMDA Antagonists. Anti Inflammatory Agents are further categorized into Cytokine Inhibitor Anti Inflammatory Agents, NSAID Anti Inflammatory Agents, and Steroid Anti Inflammatory Agents, which influence safety monitoring and chronic use considerations. Antioxidant strategies include Flavonoid Antioxidants, Vitamin C Antioxidants, and Vitamin E Antioxidants, each with different pharmacokinetic and formulation profiles. Within Calcium Channel Blockers, distinctions between Flunarizine Calcium Channel Blockers and Nimodipine Calcium Channel Blockers affect clinical application, while NMDA Antagonists subdivide into Ketamine NMDA Antagonists and Memantine NMDA Antagonists, reflecting divergent dosing paradigms and therapeutic contexts.

Based on End User, the primary care contexts include Clinics, Home Healthcare, Hospitals, and Research Institutes, each presenting distinct procurement cycles, storage capabilities, and lifecycle management demands. Based on Indication, therapeutic targeting spans Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Spinal Cord Injury, Stroke, and Traumatic Brain Injury, with granular subpopulations such as Early Stage Alzheimer's Disease, Moderate Stage Alzheimer's Disease, Severe Stage Alzheimer's Disease, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Postural Instability Parkinson's Disease, Tremor Dominant Parkinson's Disease, Hemorrhagic Stroke, and Ischemic Stroke informing clinical trial design and outcome selection. Based on Distribution Channel, suppliers must consider the practicalities of Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies when devising launch and access strategies.

Taken together, these segmentation insights underscore the importance of aligning development strategy with the specific regulatory, logistical, and clinical realities of each therapeutic and distribution pathway. Cross-segment synergies, such as pairing neurotrophic factor biologics with targeted delivery systems for defined indication subtypes, can create differentiated value propositions when matched to the operational capacities of end users and distribution channels.

Regional strategic implications across major geographies that influence regulatory planning, manufacturing footprint decisions, clinical operations, and access pathways

Regional dynamics are critical for sculpting commercial strategy, clinical trial design, manufacturing footprint, and regulatory engagement. The Americas continue to be a focal point for advanced clinical development and commercialization given established payer structures and high-density research infrastructure, but regional reimbursement nuances and procurement processes require tailored value dossiers and evidence packages. In Europe, Middle East & Africa, regulatory harmonization trends and country-specific health technology assessment practices necessitate early alignment on endpoints and budget impact considerations, and emerging markets within the region may present opportunities for real-world data collection and post-authorization access programs.

Asia-Pacific presents a diverse environment where regulatory maturity varies widely and where local manufacturing and contract development capabilities can offer strategic advantages. In many countries across the region, initiatives to accelerate domestic capacity for biologics and advanced therapies can shorten supply chain routes and reduce exposure to cross-border trade friction. Therefore, biopharmaceutical leaders should deploy differentiated strategies that account for regional regulatory ecosystems, distribution infrastructure, and payer expectations, while proactively engaging local clinical and manufacturing partners to optimize trial recruitment, localization of supply, and long-term access.

Competitive and collaborative company-level trends highlighting platform investments, strategic alliances, and specialized manufacturing capabilities driving therapeutic advancement

The competitive and collaborative landscape in neuroprotection is characterized by a mix of established pharmaceutical companies, specialized biotechnology firms, academic translational centers, and contract service providers. Key organizations are concentrating on platform technologies for targeted delivery, modular manufacturing for biologics and cell therapies, and translational biomarker programs that can de-risk late-stage development. Partnerships between innovators and large-scale manufacturers are increasingly common to reconcile the capital intensity of complex therapeutic production with the need for scalable supply chains.

Moreover, research institutes and clinical networks are acting as crucial nodes for validating novel mechanisms and enabling adaptive trial designs that prioritize patient-relevant endpoints. Strategic alliances that combine deep mechanistic expertise with commercialization capabilities can accelerate time-to-access while managing development risk. In parallel, contract research and manufacturing organizations that invest in specialized cleanroom facilities, cold-chain logistics, and regulatory support services are becoming essential enablers for companies seeking to commercialize advanced neuroprotective modalities at scale.

Practical strategic recommendations for senior leaders to align scientific investment, supply chain resilience, and value demonstration in neuroprotective therapy development

Industry leaders should adopt an integrated approach that aligns scientific prioritization with pragmatic supply chain, regulatory, and commercial planning. First, organizations must prioritize cross-functional scenario planning that incorporates regulatory pathway contingencies, supplier continuity plans, and reimbursement evidence strategies to reduce program vulnerability. Early investment in biomarker validation and real-world evidence frameworks will enhance the persuasiveness of clinical claims and payor discussions, particularly for therapies that rely on surrogate endpoints or novel mechanisms.

Second, forging selective partnerships with contract development and manufacturing organizations, academic translational hubs, and commercialization specialists can distribute risk while concentrating internal resources on core scientific differentiators. Third, companies should consider regional manufacturing or licensed local supply arrangements to mitigate trade-related disruptions and to expedite access in jurisdictions with distinct regulatory or procurement processes. Finally, a sustained focus on post-approval performance measurement, patient adherence support, and outcomes-based contracting will be critical to securing long-term access and demonstrating value to health systems and payers.

Transparent description of primary and secondary research methods, evidence synthesis approaches, and validation steps used to generate practical neuroprotection insights

This research synthesis combines primary interviews with clinical investigators, manufacturing and procurement leaders, regulatory specialists, and commercial strategists together with systematic secondary literature review of peer-reviewed translational science, regulatory guidance documents, and published clinical trial methodology. Evidence synthesis emphasized mechanism-specific clinical outcomes, manufacturing process dependencies, and care delivery pathway considerations to ensure that insights reflect operational as well as scientific realities.

Analytical methods included qualitative triangulation across stakeholder perspectives, scenario analysis to assess supply chain and policy sensitivities, and comparative evaluation of regulatory pathways relevant to biologics, small molecules, gene therapies, and cell-based interventions. Data quality controls included source cross-validation, investigator corroboration of clinical assumptions, and iterative validation with subject matter experts to ensure the robustness and applicability of recommendations for decision-makers.

Synthesis of strategic imperatives that connect translational science, operational resilience, and evidence-generation to realize clinical impact in neuroprotection

In conclusion, neuroprotection is entering an era where mechanistic precision, delivery innovation, and integrated evidence strategies are converging to create differentiated clinical opportunities. Success will depend on the capacity to translate laboratory insights into robust clinical programs while simultaneously managing the operational realities of complex manufacturing, distributed supply chains, and payer expectations. Stakeholders who align early on biomarker strategies, regional manufacturing considerations, and partnership models are better positioned to mitigate development risk and to accelerate clinical impact.

Looking forward, the interplay between scientific novelty and pragmatic execution will determine which therapies achieve durable clinical adoption. By embedding regulatory foresight, procurement resilience, and real-world performance measurement into program design, organizations can enhance the probability that promising neuroprotective interventions will reach the patients who need them most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of gene editing therapies targeting neuroinflammation pathways in multiple sclerosis patients
  • 5.2. Adoption of wearable neurostimulation devices for personalized management of chronic migraine symptoms
  • 5.3. Integration of AI-driven biomarkers for early Alzheimer's disease diagnosis and progression monitoring
  • 5.4. Development of blood-brain barrier-penetrant small molecules for acute ischemic stroke intervention
  • 5.5. Rising investment in cell-based therapies harnessing neural stem cells for spinal cord injury repair
  • 5.6. Utilization of lipid nanoparticle platforms for RNA-based neuroprotective treatment in Parkinson's disease

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuroprotection Market, by Product Type

  • 8.1. Biologics
    • 8.1.1. Monoclonal Antibody Biologics
    • 8.1.2. Neurotrophic Factor Biologics
  • 8.2. Drugs
    • 8.2.1. Peptide Drugs
    • 8.2.2. Small Molecule Drugs
  • 8.3. Gene Therapy
  • 8.4. Nutraceuticals
    • 8.4.1. Herbal Extract Nutraceuticals
    • 8.4.2. Mineral Nutraceuticals
    • 8.4.3. Vitamin Nutraceuticals
  • 8.5. Stem Cell Therapy

9. Neuroprotection Market, by Mechanism Of Action

  • 9.1. Anti Inflammatory Agents
    • 9.1.1. Cytokine Inhibitor Anti Inflammatory Agents
    • 9.1.2. NSAID Anti Inflammatory Agents
    • 9.1.3. Steroid Anti Inflammatory Agents
  • 9.2. Antioxidants
    • 9.2.1. Flavonoid Antioxidants
    • 9.2.2. Vitamin C Antioxidants
    • 9.2.3. Vitamin E Antioxidants
  • 9.3. Calcium Channel Blockers
    • 9.3.1. Flunarizine Calcium Channel Blockers
    • 9.3.2. Nimodipine Calcium Channel Blockers
  • 9.4. Glutamate Inhibitors
  • 9.5. Neurotrophic Factors
  • 9.6. NMDA Antagonists
    • 9.6.1. Ketamine NMDA Antagonists
    • 9.6.2. Memantine NMDA Antagonists

10. Neuroprotection Market, by End User

  • 10.1. Clinics
  • 10.2. Home Healthcare
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Neuroprotection Market, by Indication

  • 11.1. Alzheimer's Disease
    • 11.1.1. Early Stage Alzheimer's Disease
    • 11.1.2. Moderate Stage Alzheimer's Disease
    • 11.1.3. Severe Stage Alzheimer's Disease
  • 11.2. Multiple Sclerosis
    • 11.2.1. Relapsing Remitting Multiple Sclerosis
    • 11.2.2. Secondary Progressive Multiple Sclerosis
  • 11.3. Parkinson's Disease
    • 11.3.1. Postural Instability Parkinson's Disease
    • 11.3.2. Tremor Dominant Parkinson's Disease
  • 11.4. Spinal Cord Injury
  • 11.5. Stroke
    • 11.5.1. Hemorrhagic Stroke
    • 11.5.2. Ischemic Stroke
  • 11.6. Traumatic Brain Injury

12. Neuroprotection Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Neuroprotection Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neuroprotection Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neuroprotection Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Eli Lilly and Company
    • 16.3.2. Roche Holding AG
    • 16.3.3. Novartis AG
    • 16.3.4. AstraZeneca PLC
    • 16.3.5. Biogen Inc.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. AbbVie Inc.
    • 16.3.8. Johnson & Johnson
    • 16.3.9. Merck & Co., Inc.
    • 16.3.10. GlaxoSmithKline plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEUROPROTECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROPROTECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROPROTECTION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL NEUROPROTECTION MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL NEUROPROTECTION MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL NEUROPROTECTION MARKET SIZ